Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases.
The multi-target project will focus on orphan G protein-coupled receptors (GPCRs), which are said to be one of the main therapeutic target classes. Though drugs targeting GPCRs constitute nearly 40% of all treatments on the market, only 15% of them are addressed.
Go deeper with GlobalData
The partners will leverage Domain’s DTect-All and bioSens-All platforms to identify new GPCR treatments for neuropsychiatric disorders.
Domain platforms are designed to characterise small molecule GPCR binders to screen as well as characterise potential lead compounds.
The company’s GPCR experts will also participate in the drug discovery project to support with knowledge and insights during the discovery phase.
Boehringer Ingelheim CNS Diseases Research global head Bernd Sommer said: “We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”
The German pharmaceutical company will make an upfront payment to Domain, along with potential discovery, development and commercial milestones as well as royalties on sales.
Domain Therapeutics CEO Pascal Neuville said: “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets, and, coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”
The specific financial details of the deal have not been disclosed.
